The Japan Patent Office has granted Avita Medical a Japanese patent entitled: Improved drug delivery device and methods therefore. The intellectual property covered under the patent follows patents
GlaxoSmithKline (GSK) has provided an update on orders received for its pandemic (H1N1) adjuvanted vaccine. Reportedly, on 4th August, GSK confirmed that it had contracts in place to
OncoGenex has received an additional Fast Track Designation from FDA for OGX-011 (also known as custirsen sodium) for progressive metastatic prostate cancer, in combination with first-line docetaxel treatment.
GlaxoSmithKline (GSK) has entered into a long-term joint venture with Jiangsu Walvax Biotech (Walvax) to develop and manufacture paediatric vaccines for the Chinese market. Reportedly, the joint venture
R-Tech Ueno has initiated early phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company – a new compound targeted as a
Wyatt Technology has reported that Pfizer has chosen its DAWN HELEOS Multi-Angle Light Scattering (MALS) instrument to monitor protein reagent quality in drug discovery. Reportedly, the instrument’s analytical
BioDelivery Sciences has received a $1.3m grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B to further study the formulation in the treatment of
Acadia Pharmaceuticals has provided an update on its phase III program with pimavanserin for Parkinson’s disease psychosis (PDP). The trial is being conducted in collaboration with Biovail Laboratories,
TOPICA Pharmaceuticals has announced results from its phase 2 clinical study evaluating luliconazole, in patients with tinea pedis (athlete’s foot). The study was designed to assess the effectiveness
Imedicor has signed an agreement with Dallas-based Access Pharmaceuticals for the North American commercial launch of MuGard, its FDA-approved oral wound rinse for the management of oral mucositis
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.